Ingredients produced with the help of gene technology, so-called recombinant ingredients, are gaining ground in the biopharmaceutical industry. Novozymes came a big step closer to its goal of being a leading supplier of recombinant ingredients in 2006 with the acquisitions of UK company Delta and Australian company GroPep.